Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

What I Have Learned Since Fellowship: Tips for Professional Success and Happiness

June 20th 2011

Tips for success from Lawrence B. Afrin, MD an associate professor of medicine in the Division of Hematology/Oncology at Medical University of South Carolina in Charleston.

FDA Extends Uses for the Lymphoma Drug Istodax

June 17th 2011

The FDA has granted accelerated approval for Istodax (romidepsin) to be used as treatment for an aggressive form of non-Hodgkin lymphoma

Dr. Kris Discusses Methotrexate in ALL

June 14th 2011

Dr Kris From Memorial Sloan-Kettering Cancer Center Discusses Methotrexate in Acute Lymphocytic Leukemia

Disease States: Hematologic Cancers

June 8th 2011

Hematologic cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

June 4th 2011

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High-Dose Methotrexate Better for ALL

June 4th 2011

High doses of methotrexate increases EFS for children and young adults

Canine DNA Yields Clues to Human Lymphomas

June 3rd 2011

Researchers at North Carolina State University used canines as genetic models for studying lymphomas

Reynaldo Garcia Explains the BCR-ABL Study

May 31st 2011

Reynaldo Garcia from the UNC Lineberger Comprehensive Cancer Center Explains the BCR-ABL Study

Reynaldo Garcia on BCR-ABL Testing in CML

May 27th 2011

Reynaldo Garcia from the University of North Carolina Lineberger Comprehensive Cancer Center on BCR-ABL Testing in Chronic Myelogenous Leukemia

Climbing to New Heights: James Berenson, MD, and the Institute for Myeloma and Bone Cancer Research

May 27th 2011

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.

Revlimid Results for Multiple Myeloma Deemed "Historic"

May 6th 2011

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

38 Multiple Myeloma Tumor Genes Mapped

May 5th 2011

Researchers have sequenced 38 tumor genomes from patients with multiple myeloma (MM), comparing them with normal DNA.

FDA Accepts BLA Filings for Lymphoma Treatments

May 3rd 2011

Seattle Genetics, Inc announced on Monday that the FDA has accepted filings for two Biologics License Applications for bretuximab vedotin

ASH Presses for Action on Hematology Drug Shortages

April 27th 2011

The American Society of Hematology (ASH) is sounding a fresh alarm about ongoing supply problems with oncology drugs

FDA Notes Increase in Rare Blood Cancers Associated with TNF Blockers

April 14th 2011

The FDA reported today that TNF blockers may be responsible for an increased incidence of HSTCL in adolescents and young adults

Medical Professionals and Social Networking: The Opportunities, Challenges, and Risks

April 11th 2011

The brave, (relatively) new world of social networking has presented even the medical community with challenges, but with a few precautions fellows can avoid some of the pitfalls associated with an online presence.

Landmark Genome Analysis to Drive Multiple Myeloma Research

March 28th 2011

Genome sequencing may help researchers understand the pathogenesis of this cancer, which despite exhaustive research, is only partially understood

Tool Maps a Rare Disease

March 28th 2011

A new tool for mapping disease severity and outcomes in patients with Gaucher disease (GD) may help physicians develop a standardized approach to treatment

Dr. Jabbour on Front-Line Treatments for CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Dr. Jabbour on Second-Generation TKIs in CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.